Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

• Status: Recruiting
• Trial end date: 2024-08-01

Summary

Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).

• Phase: Phase 3

Details

• Lead Sponsor: Meiji Seika Pharma Co., Ltd.
• Treatments: Aztreonam; Cefepime; Cilastatin; Imipenem